These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25900274)

  • 1. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
    Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
    Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
    J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
    Lin CY; Lin CL; Huang WS; Kao CH
    J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
    Rosario PW; Calsolari MR
    Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review.
    Clement SC; Peeters RP; Ronckers CM; Links TP; van den Heuvel-Eibrink MM; Nieveen van Dijkum EJ; van Rijn RR; van der Pal HJ; Neggers SJ; Kremer LC; van Eck-Smit BL; van Santen HM
    Cancer Treat Rev; 2015 Dec; 41(10):925-34. PubMed ID: 26421813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
    Raza H; Khan AU; Hameed A; Khan A
    Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study.
    Lin CM; Doyle P; Tsan YT; Lee CH; Wang JD; Chen PC;
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):253-9. PubMed ID: 23982456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma.
    Fard-Esfahani A; Mirshekarpour H; Fallahi B; Eftekhari M; Saghari M; Beiki D; Ansari-Gilani K; Takavar A
    Clin Nucl Med; 2007 Sep; 32(9):696-9. PubMed ID: 17710021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
    Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
    J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
    Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
    Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.
    Nabaa B; Takahashi K; Sasaki T; Okizaki A; Aburano T
    AJNR Am J Neuroradiol; 2012 Nov; 33(10):1964-70. PubMed ID: 22555571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Lam MG; van Isselt JW
    J Nucl Med; 2005 Dec; 46(12):2118; author reply 2118-9. PubMed ID: 16330579
    [No Abstract]   [Full Text] [Related]  

  • 19. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
    Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
    Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.